Skip to main content
Erschienen in: Calcified Tissue International 3/2021

23.11.2020 | Original Research

Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA)

verfasst von: M. Hagelstein-Rotman, M. E. Meier, B. C. J. Majoor, A. H. G. Cleven, P. D. S. Dijkstra, N. A. T. Hamdy, M. A. J. van de Sande, O. M. Dekkers, N. M. Appelman-Dijkstra

Erschienen in: Calcified Tissue International | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Malignant transformation of fibrous dysplasia lesions has been reported in patients with fibrous dysplasia/McCune-Albright syndrome (FD/MAS). Recently, we have observed an increased risk for breast cancer. In this study, the prevalence of skeletal and extraskeletal malignancies in patients with FD/MAS in the Netherlands was assessed by analyzing data from our cohort of FD/MAS patients, the Dutch Pathology Registry (PALGA), and the Netherlands Cancer Registry (NCR). We extracted data on sex, age at diagnosis of FD/MAS, type of FD/MAS, type of malignancy, and age at diagnosis of malignancy and histology of bone and malignant tissue when available, including GNAS-mutation analysis from patients’ medical records. Standardized Morbidity Ratios (SMRs) with 95% confidence intervals were calculated. Twelve malignancies were identified in the LUMC FD/MAS cohort and 100 in the PALGA cohort. In this cohort, SMR was increased for osteosarcoma (19.7, 95% CI 3.5–48.9), cervical cancer (4.93, 95%CI 1.7–8.2), thyroid cancer (3.71, 95% CI 1.1–7.8), prostate cancer (3.08, 95% CI 1.8–4.6), and melanoma (2.01, 95%CI 1.2–3.1). SMRs for pancreatic cancer or hepatocellular carcinoma could not be calculated due to low numbers. The small number of malignancies identified in our FD/MAS cohort precluded the calculation of SMRs for our cohort specifically. Our findings show that patients with FD/MAS appear to have an increased risk for osteosarcoma, cervical, thyroid, and prostate cancer and melanoma. However, these data should be interpreted with caution, as true incidence rates of the identified malignancies may be influenced by the inclusion of only patients with histologically confirmed FD/MAS. The etiology of this increased risk for malignancies still needs to be elucidated.
Literatur
1.
Zurück zum Zitat Weinstein LSLJ, Sakamoto A, Xie T, Chen M (2004) Minireview: GNAS: normal and abnormal functions. Endocrinology 145(12):5459–5464PubMed Weinstein LSLJ, Sakamoto A, Xie T, Chen M (2004) Minireview: GNAS: normal and abnormal functions. Endocrinology 145(12):5459–5464PubMed
2.
Zurück zum Zitat O’Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS (2013) The emerging mutational landscape of G-proteins and G-protein coupled receptors in cancer. Nat Rev Cancer 13(6):412–424PubMedPubMedCentral O’Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS (2013) The emerging mutational landscape of G-proteins and G-protein coupled receptors in cancer. Nat Rev Cancer 13(6):412–424PubMedPubMedCentral
3.
Zurück zum Zitat Boyce AMCW, Shawker TH, Pinto PA, Linehan WM, Bhattacharryya N, Merino MJ, Singer FR, Collins MT (2012) Characterization and management of testicular pathology in McCune-albright syndrome. J Clin Endocrinol Metab 97(9):E1782–E1790PubMedPubMedCentral Boyce AMCW, Shawker TH, Pinto PA, Linehan WM, Bhattacharryya N, Merino MJ, Singer FR, Collins MT (2012) Characterization and management of testicular pathology in McCune-albright syndrome. J Clin Endocrinol Metab 97(9):E1782–E1790PubMedPubMedCentral
4.
Zurück zum Zitat Penn DL, Tartarini RJ, Glass CH, De Girolami U, Zamani AA, Dunn IF (2017) Natural history of cranial fibrous dysplasia revealed during long-term follow-up: case report and literature review. Surg Neurol Int 8:209PubMedPubMedCentral Penn DL, Tartarini RJ, Glass CH, De Girolami U, Zamani AA, Dunn IF (2017) Natural history of cranial fibrous dysplasia revealed during long-term follow-up: case report and literature review. Surg Neurol Int 8:209PubMedPubMedCentral
5.
Zurück zum Zitat DiCaprio MREW (2005) Fibrous dysplasia. Pathophysiology, evaluation and treatment. J Bone Joint Surg Am 87(8):1848–1864PubMed DiCaprio MREW (2005) Fibrous dysplasia. Pathophysiology, evaluation and treatment. J Bone Joint Surg Am 87(8):1848–1864PubMed
6.
Zurück zum Zitat Riddle NDBM (2013) Fibrous dysplasia. Arch Pathol Lab Med 137(1):134–138PubMed Riddle NDBM (2013) Fibrous dysplasia. Arch Pathol Lab Med 137(1):134–138PubMed
7.
Zurück zum Zitat Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM, Leithner A, Jutte PC, Velez R et al (2019) Prevalence and clinical features of mazabraud syndrome: a multicenter European study. J Bone Joint Surg Am 101(2):160–168PubMed Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM, Leithner A, Jutte PC, Velez R et al (2019) Prevalence and clinical features of mazabraud syndrome: a multicenter European study. J Bone Joint Surg Am 101(2):160–168PubMed
8.
Zurück zum Zitat Wood LD, Noe M, Hackeng W, Brosens LA, Bhaijee F, Debeljak M et al (2017) Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch 470(4):391–400PubMedPubMedCentral Wood LD, Noe M, Hackeng W, Brosens LA, Bhaijee F, Debeljak M et al (2017) Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch 470(4):391–400PubMedPubMedCentral
9.
Zurück zum Zitat Parvanescu ACJ, Ronot M, Hentic O, Grybek V, Couvelard A, Levy P, Chanson P, Ruszniewski P, Sauvanet A, Gaujoux S (2014) Lessons from McCune-albright syndrome-associated intraductal papillary mucinous neoplasms—GNAS-activating mutations in pancreatic carcinogenesis. JAMA Surg 149(8):858–862PubMed Parvanescu ACJ, Ronot M, Hentic O, Grybek V, Couvelard A, Levy P, Chanson P, Ruszniewski P, Sauvanet A, Gaujoux S (2014) Lessons from McCune-albright syndrome-associated intraductal papillary mucinous neoplasms—GNAS-activating mutations in pancreatic carcinogenesis. JAMA Surg 149(8):858–862PubMed
10.
Zurück zum Zitat Gaujoux SSS, Ronot M, Rangheard AS, Cros J, Belghiti J, Sauvanet A, Ruszniewski P, Chanson P (2014) Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 99(1):E97-101PubMed Gaujoux SSS, Ronot M, Rangheard AS, Cros J, Belghiti J, Sauvanet A, Ruszniewski P, Chanson P (2014) Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 99(1):E97-101PubMed
11.
Zurück zum Zitat Collins MTSN, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A (2003) Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 88(9):4413–4417PubMed Collins MTSN, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A (2003) Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 88(9):4413–4417PubMed
12.
Zurück zum Zitat Chevalier NPF, Fontana S, Delotte J, Gaspari L, Ferrari P, Sultan C, Fénichel P (2015) Postpubertal persistent hyperestrogenemia in McCune-albright syndrome: unilateral oophorectomy improved fertility but detected an unexpected borderline epithelial ovarian tumor. J Periatr Adolesc Gynecol 28(6):e169–e172 Chevalier NPF, Fontana S, Delotte J, Gaspari L, Ferrari P, Sultan C, Fénichel P (2015) Postpubertal persistent hyperestrogenemia in McCune-albright syndrome: unilateral oophorectomy improved fertility but detected an unexpected borderline epithelial ovarian tumor. J Periatr Adolesc Gynecol 28(6):e169–e172
13.
Zurück zum Zitat Huston TLSR (2004) Ductal carcinoma in situ in a 27-year-old woman with McCune-albright syndrome. Breast J 10(5):440–442PubMed Huston TLSR (2004) Ductal carcinoma in situ in a 27-year-old woman with McCune-albright syndrome. Breast J 10(5):440–442PubMed
14.
Zurück zum Zitat Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Van Nhieu JT, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 56(1):184–191PubMed Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Van Nhieu JT, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 56(1):184–191PubMed
15.
Zurück zum Zitat Majoor BC, Boyce AM, Bovee JV, Smit VT, Collins MT, Cleton-Jansen AM et al (2018) Increased risk of breast cancer at a young age in women with fibrous dysplasia. J Bone Miner Res 33(1):84–90PubMed Majoor BC, Boyce AM, Bovee JV, Smit VT, Collins MT, Cleton-Jansen AM et al (2018) Increased risk of breast cancer at a young age in women with fibrous dysplasia. J Bone Miner Res 33(1):84–90PubMed
16.
Zurück zum Zitat Matsubara A, Sekine S, Kushima R, Ogawa R, Taniguchi H, Tsuda H et al (2013) Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum. J Pathol 229(4):579–587PubMed Matsubara A, Sekine S, Kushima R, Ogawa R, Taniguchi H, Tsuda H et al (2013) Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum. J Pathol 229(4):579–587PubMed
17.
Zurück zum Zitat van den Hurk K, Balint B, Toomey S, O’Leary PC, Unwin L, Sheahan K et al (2015) High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res 25(3):189–199PubMed van den Hurk K, Balint B, Toomey S, O’Leary PC, Unwin L, Sheahan K et al (2015) High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res 25(3):189–199PubMed
18.
Zurück zum Zitat Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW et al (2005) The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14(4):871–877PubMed Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW et al (2005) The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14(4):871–877PubMed
19.
Zurück zum Zitat Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19–24PubMedPubMedCentral Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19–24PubMedPubMedCentral
20.
Zurück zum Zitat Nomura R, Saito T, Mitomi H, Hidaka Y, Lee SY, Watanabe S et al (2014) GNAS mutation as an alternative mechanism of activation of the Wnt/beta-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum Pathol 45(12):2488–2496PubMed Nomura R, Saito T, Mitomi H, Hidaka Y, Lee SY, Watanabe S et al (2014) GNAS mutation as an alternative mechanism of activation of the Wnt/beta-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum Pathol 45(12):2488–2496PubMed
21.
Zurück zum Zitat Matsubara A, Sekine S, Ogawa R, Yoshida M, Kasamatsu T, Tsuda H et al (2014) Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations. Am J Surg Pathol 38(3):370–376PubMed Matsubara A, Sekine S, Ogawa R, Yoshida M, Kasamatsu T, Tsuda H et al (2014) Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations. Am J Surg Pathol 38(3):370–376PubMed
22.
Zurück zum Zitat IKNL. Nederlandse Kankerregistratie. 2017. IKNL. Nederlandse Kankerregistratie. 2017.
23.
Zurück zum Zitat Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192PubMed Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192PubMed
24.
Zurück zum Zitat Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP (1999) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome. Skeletal Radiol 28:522–526PubMed Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP (1999) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome. Skeletal Radiol 28:522–526PubMed
25.
Zurück zum Zitat Qu N, Yao W, Cui X, Zhang H (2015) Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review. Medicine (Baltimore) 94(3):e369 Qu N, Yao W, Cui X, Zhang H (2015) Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review. Medicine (Baltimore) 94(3):e369
26.
Zurück zum Zitat Schwartz DTAM (1964) The malignant transformation of fibrous dysplasia. Am J Med Si 247:1–20 Schwartz DTAM (1964) The malignant transformation of fibrous dysplasia. Am J Med Si 247:1–20
27.
Zurück zum Zitat Ruggieri PSF, Bond JR, Unni KK (1994) Malignancies in fibrous dysplasia. Cancer 73(5):1411–1423PubMed Ruggieri PSF, Bond JR, Unni KK (1994) Malignancies in fibrous dysplasia. Cancer 73(5):1411–1423PubMed
28.
Zurück zum Zitat Dumitrescu CE, Collins MT (2008) McCune-Albright syndrome Orphanet. J Rare Dis 3:12 Dumitrescu CE, Collins MT (2008) McCune-Albright syndrome Orphanet. J Rare Dis 3:12
29.
Zurück zum Zitat Jhala DNEI, Carroll AJ, Lopez-Ben R, Lopez-Terrada D, Rao PH, Pettenati MJ, Siegal GP (2003) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome: a case report emphasizing the cytological and cytogenetic findings. Hum Pathol 34(12):1354–1357PubMed Jhala DNEI, Carroll AJ, Lopez-Ben R, Lopez-Terrada D, Rao PH, Pettenati MJ, Siegal GP (2003) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome: a case report emphasizing the cytological and cytogenetic findings. Hum Pathol 34(12):1354–1357PubMed
30.
Zurück zum Zitat Collins MT, Bianco P et al (2013) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, Hoboken Collins MT, Bianco P et al (2013) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, Hoboken
31.
Zurück zum Zitat Collins MT, Singer FR, Eugster E (2012) McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 7(Suppl 1):4 Collins MT, Singer FR, Eugster E (2012) McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 7(Suppl 1):4
32.
Zurück zum Zitat Lopez-Ben RPM, Jaffe KA, Siegal GP (1999) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome. Skelet Radiol 28(9):522–526 Lopez-Ben RPM, Jaffe KA, Siegal GP (1999) Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud’s syndrome. Skelet Radiol 28(9):522–526
33.
Zurück zum Zitat Liu FLW, Yao Y, Li G, Yang Y, Dou W, Zhong D, Wang L, Zhu X, Hu H, Zhang J, Wang R, Chen G (2011) A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy. J Periatr Endocrinol Metab 24(5–6):283–287 Liu FLW, Yao Y, Li G, Yang Y, Dou W, Zhong D, Wang L, Zhu X, Hu H, Zhang J, Wang R, Chen G (2011) A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy. J Periatr Endocrinol Metab 24(5–6):283–287
34.
Zurück zum Zitat Ruchala M, Wolinski K (2019) Health-related complications of acromegaly-risk of malignant neoplasms. Front Endocrinol 10:268 Ruchala M, Wolinski K (2019) Health-related complications of acromegaly-risk of malignant neoplasms. Front Endocrinol 10:268
35.
Zurück zum Zitat Shanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M (2016) Is there a role for IGF-1 in the development of second primary cancers? Cancer Med 5(11):3353–3367PubMedPubMedCentral Shanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M (2016) Is there a role for IGF-1 in the development of second primary cancers? Cancer Med 5(11):3353–3367PubMedPubMedCentral
36.
Zurück zum Zitat Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S et al (2007) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 16(6):1121–1127PubMed Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S et al (2007) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 16(6):1121–1127PubMed
37.
Zurück zum Zitat Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S et al (2000) Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85(8):2744–2747PubMed Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S et al (2000) Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85(8):2744–2747PubMed
38.
Zurück zum Zitat Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108(2):262–268PubMed Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108(2):262–268PubMed
39.
Zurück zum Zitat Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y et al (2009) Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a nested case-control study in large scale cohort study in Japan. Asian Pac J Cancer Prev 10(Suppl):57–61PubMed Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y et al (2009) Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a nested case-control study in large scale cohort study in Japan. Asian Pac J Cancer Prev 10(Suppl):57–61PubMed
40.
Zurück zum Zitat Pham TM, Fujino Y, Kikuchi S, Tamakoshi A, Yatsuya H, Matsuda S et al (2007) A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer 43(10):1611–1616PubMed Pham TM, Fujino Y, Kikuchi S, Tamakoshi A, Yatsuya H, Matsuda S et al (2007) A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer 43(10):1611–1616PubMed
41.
Zurück zum Zitat Sakauchi F, Nojima M, Mori M, Wakai K, Suzuki S, Tamakoshi A et al (2009) Serum insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and risk of breast cancer in the Japan Collaborative Cohort study. Asian Pac J Cancer Prev 10(Suppl):51–55PubMed Sakauchi F, Nojima M, Mori M, Wakai K, Suzuki S, Tamakoshi A et al (2009) Serum insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and risk of breast cancer in the Japan Collaborative Cohort study. Asian Pac J Cancer Prev 10(Suppl):51–55PubMed
42.
Zurück zum Zitat Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11(11):1413–1418PubMed Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11(11):1413–1418PubMed
43.
Zurück zum Zitat Suzuki S, Kojima M, Tokudome S, Suzuki K, Ozasa K, Ito Y et al (2009) Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control study in the Japan collaborative cohort study. Asian Pac J Cancer Prev 10(Suppl):45–49PubMed Suzuki S, Kojima M, Tokudome S, Suzuki K, Ozasa K, Ito Y et al (2009) Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control study in the Japan collaborative cohort study. Asian Pac J Cancer Prev 10(Suppl):45–49PubMed
44.
Zurück zum Zitat Weinstein LSSA, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune–albright syndrome. N Engl J Med 325(24):1688–1695PubMed Weinstein LSSA, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune–albright syndrome. N Engl J Med 325(24):1688–1695PubMed
45.
Zurück zum Zitat Szuhai K, Cleton-Jansen AM, Hogendoorn PC, Bovee JV (2012) Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 205(5):193–204PubMed Szuhai K, Cleton-Jansen AM, Hogendoorn PC, Bovee JV (2012) Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 205(5):193–204PubMed
46.
Zurück zum Zitat Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20(5):230–236PubMed Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20(5):230–236PubMed
47.
Zurück zum Zitat Boyce AM, Florenzano P, de Castro LF, Collins MT (1993) Fibrous dysplasia/McCune-albright syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al (eds) GeneReviews . University of washington, Seattle WA Boyce AM, Florenzano P, de Castro LF, Collins MT (1993) Fibrous dysplasia/McCune-albright syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al (eds) GeneReviews . University of washington, Seattle WA
48.
Zurück zum Zitat Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130(3):456–469PubMedPubMedCentral Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130(3):456–469PubMedPubMedCentral
49.
Zurück zum Zitat Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 16(6):373–386PubMed Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 16(6):373–386PubMed
50.
Zurück zum Zitat Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M (2015) FGF23 promotes prostate cancer progression. Oncotarget 6(19):17291–17301PubMedPubMedCentral Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M (2015) FGF23 promotes prostate cancer progression. Oncotarget 6(19):17291–17301PubMedPubMedCentral
51.
Zurück zum Zitat de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR (2018) The anti-tumor effect of RANKL inhibition in malignant solid tumors—a systematic review. Cancer Treat Rev 62:18–28PubMed de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR (2018) The anti-tumor effect of RANKL inhibition in malignant solid tumors—a systematic review. Cancer Treat Rev 62:18–28PubMed
Metadaten
Titel
Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA)
verfasst von
M. Hagelstein-Rotman
M. E. Meier
B. C. J. Majoor
A. H. G. Cleven
P. D. S. Dijkstra
N. A. T. Hamdy
M. A. J. van de Sande
O. M. Dekkers
N. M. Appelman-Dijkstra
Publikationsdatum
23.11.2020
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 3/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-020-00780-6

Weitere Artikel der Ausgabe 3/2021

Calcified Tissue International 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.